Skip to content

John A. Henry

3 papers in the library · 338 citations · publishing 2002-2003

Papers

Acute, sub‐acute and long‐term subjective consequences of ‘ecstasy’ (MDMA) consumption in 430 regular users

Human Psychopharmacology Clinical and Experimental October 1, 2003 Suzanne L. Verheyden, John A. Henry, H. Valerie Curran 171 citations

Regular MDMA users report both positive and negative psychological effects. Among 466 regular users, acute effects include positive and negative impacts on mental health and physical effects. Between sessions, 83% experienced low mood and 80% impaired concentration. Long-term effects include tolerance (59%), impaired concentration (38%), depression (37%), and feeling more open toward people (31%). Factors such as age, gender, extent of MDMA use, and use of cocaine or amphetamine influence these effects. Users' main concern about stopping MDMA is its long-term effects on mental health.

Death following ingestion of MDMA (ecstasy) and moclobemide

Addiction February 20, 2003 Erkki Vuori, John A. Henry, Ilkka Ojanperä et al. 113 citations

Four deaths occurred after people took moclobemide and MDMA ('ecstasy') together. The likely cause of death in each case was serotonin syndrome, a dangerous condition caused by the interaction between the two drugs. None of the victims had a prescription for moclobemide; each apparently took it to boost the effects of MDMA, leading to fatal outcomes. The authors call for warnings against uninformed efforts to enhance the effects of illicit drugs.

Action of MDMA (Ecstasy) and Its Metabolites on Arginine Vasopressin Release

Annals of the New York Academy of Sciences June 1, 2002 John K. Fallon, Dhwanil Shah, Andrew T. Kicman et al. 54 citations

MDMA (ecstasy) can cause dangerously low sodium levels by triggering inappropriate secretion of the antidiuretic hormone arginine vasopressin (AVP). In eight healthy men given a low 40 mg dose of MDMA, plasma AVP rose significantly at 1, 2, and 4 hours. A negative correlation between MDMA and AVP at 1 hour suggested a metabolite might drive the increase. Testing MDMA and five of its metabolites on isolated rat hypothalamus tissue showed all compounds increased AVP release, with the major metabolite HMMA being the most potent and DHMA the least. Most compounds also enhanced AVP release in response to potassium stimulation. These in vitro results confirm that MDMA metabolites, not just the parent drug, contribute to AVP secretion.